Bicycle Therapeutics (BCYC) Current Deferred Revenue (2018 - 2026)

Bicycle Therapeutics' Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• Quarterly Current Deferred Revenue fell 77.68% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (down 77.68% YoY) and the FY2025 annual result came in at $3.0 million, down 97.09% from the prior year.
• Current Deferred Revenue was $2.8 million for Q1 2026 at Bicycle Therapeutics, down from $3.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $135.2 million in Q4 2023 and bottomed at $1.2 million in Q2 2022.
• A 5-year average of $26.0 million and a median of $12.5 million in 2025 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue jumped 1726.95% — and 2025, when it sank 97.09%.
• Bicycle Therapeutics' Current Deferred Revenue stood at $7.4 million in 2022, then soared by 1726.95% to $135.2 million in 2023, then retreated by 24.81% to $101.7 million in 2024, then sank by 97.09% to $3.0 million in 2025, then fell by 5.61% to $2.8 million in 2026.
• Business Quant data shows BCYC's Current Deferred Revenue at $2.8 million in Q1 2026, $3.0 million in Q4 2025, and $12.3 million in Q3 2025.